SERES THERAPEUTICS INC's ticker is MCRB and the CUSIP is 81750R102. A total of 94 filers reported holding SERES THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 2.99 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $4,770,000 | +15.8% | 200,000 | 0.0% | 0.10% | +32.9% |
Q1 2021 | $4,118,000 | -16.0% | 200,000 | 0.0% | 0.07% | -30.5% |
Q4 2020 | $4,900,000 | -42.3% | 200,000 | -33.3% | 0.10% | -49.0% |
Q3 2020 | $8,493,000 | +179.2% | 300,000 | 0.0% | 0.21% | +347.8% |
Q4 2017 | $3,042,000 | -65.5% | 300,000 | -45.5% | 0.05% | -69.7% |
Q3 2017 | $8,822,000 | +30.1% | 550,000 | -8.3% | 0.15% | +28.8% |
Q2 2017 | $6,780,000 | +0.3% | 600,000 | 0.0% | 0.12% | -21.3% |
Q1 2017 | $6,762,000 | -2.4% | 600,000 | -14.3% | 0.15% | -2.6% |
Q4 2016 | $6,930,000 | +12.8% | 700,000 | +40.0% | 0.15% | +26.2% |
Q3 2016 | $6,145,000 | -31.8% | 500,000 | +61.3% | 0.12% | -34.4% |
Q2 2016 | $9,006,000 | +50.7% | 310,000 | +37.8% | 0.19% | +59.0% |
Q1 2016 | $5,976,000 | -2.7% | 225,000 | +28.6% | 0.12% | +1.7% |
Q4 2015 | $6,141,000 | +3.6% | 175,000 | -12.5% | 0.12% | -12.9% |
Q3 2015 | $5,928,000 | -10.7% | 200,000 | +25.0% | 0.13% | -53.8% |
Q2 2015 | $6,642,000 | – | 160,057 | – | 0.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Flagship Pioneering Inc. | 23,117,045 | $110,730,646 | 4.94% |
Lion Point Capital, LP | 691,803 | $3,313,736 | 1.50% |
Eversept Partners, LP | 3,076,756 | $14,737,661 | 1.23% |
Soleus Capital Management, L.P. | 2,045,983 | $9,800,259 | 1.09% |
Knott David M Jr | 470,000 | $2,251 | 0.90% |
GREAT POINT PARTNERS LLC | 938,067 | $4,493,341 | 0.88% |
Simplify Asset Management Inc. | 550,626 | $2,637,499 | 0.35% |
Delphia (USA) Inc. | 33,913 | $162,443 | 0.26% |
Alpha DNA Investment Management LLC | 138,536 | $663,587 | 0.22% |
Avoro Capital Advisors LLC | 2,500,000 | $11,975,000 | 0.16% |